Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors

Published:2013-10-03 Issue:10 Volume:38 Page:1188-1197
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Moss A. C.¹,Brinks V.²,Carpenter J. F.³

Affiliation:

1. Beth Israel Deaconess Medical Center/Harvard Medical School; Boston MA USA

2. Department of Pharmaceutics; Utrecht Institute of Pharmaceutical Sciences; Utrecht University; Utrecht The Netherlands

3. Department of Pharmaceutical Sciences; University of Colorado Anschutz Medical Campus; Aurora CO USA

Funder

NIH

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.12507/fullpdf

Reference82 articles.

1. Management of Crohn's disease in adults;Lichtenstein;Am J Gastroenterol,2009

2. Infliximab dose intensification in Crohn's disease;Regueiro;Inflamm Bowel Dis,2007

3. Loss of response and requirement of infliximab dose inten-sification in Crohn's disease: a review;Gisbert;Am J Gastroenterol,2009

4. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis;Rostholder;Aliment Pharmacol Ther,2012

5. Anti-TNF therapy in inflammatory bowel diseases: a huge review;Peyrin-Biroulet;Minerva Gastroenterol Dietol,2010

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding patient variability to biologic treatments in inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-05-03

2. Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease;Expert Opinion on Drug Metabolism & Toxicology;2024-05-03

3. Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials;Clinical and Translational Science;2024-05

4. Antibiotics influence the risk of anti-drug antibody formation during anti-TNF therapy in Chinese inflammatory bowel disease patients;Frontiers in Pharmacology;2024-04-09

5. Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD);Healthcare;2024-02-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3